Description: Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops products, such as ANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitor for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was founded in 1998 and is headquartered in Uniondale, New York.
Home Page: www.angion.com
ANGN Technical Analysis
51 Charles Lindbergh Boulevard
Uniondale,
NY
11553
United States
Phone:
415 655 4899
Officers
| Name | Title |
|---|---|
| Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. | Pres, CEO & Chairman |
| Mr. Gregory S. Curhan | Chief Financial Officer |
| Ms. Jennifer J. Rhodes J.D. | Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. |
| Mr. Daniel Iazzetti | VP of HR |
| Bruce Rich | Assistant Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4859 |
| Price-to-Sales TTM: | 0.8958 |
| IPO Date: | 2021-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 71 |